Close this search box.
Close this search box.
Close this search box.

Bormioli Pharma introduces a brand-new consultancy approach

Bormioli Pharma, an international leader in pharmaceutical packaging and medical devices, will attend Pharmapack Europe 2024 in Paris (Paris Expo, Porte de Versailles - booth B78-B79).

The exhibition will be the occasion to showcase the Company’s wide and sustainable packaging portfolio together with a strong scientific counsel approach, confirming its positioning as a solid, and reliable partner for the pharma industry.

More in detail, Bormioli Pharma reveals the latest advancements on sustainable packaging, with two primary breakthroughs in the spotlight. The first focus will be on rPET bottles, showcasing advanced recycling excellence; in fact, these bottles are produced through a depolymerization process, which allows to achieve a “virgin quality” polymer as well as a broader input material sourcing.

The second highlight will be the introduction of the new Bio PET 2.0 bottles, produced from a bio-based plastic derived from wood residues collected in responsibly managed certified forests. This material is then processed to create monoethylene glycol, used for the generation of the bioplastic polymer.

These solutions – together with 3 new responsible products that will be revealed during the trade fair – will further expand the Company’s EcoPositive range, which currently constitutes 50% of its standard catalogue and is actually the wider sustainable pharma packaging offerings on the international market.

Pharmapack Europe 2024 will also be the occasion to introduce Bormioli Pharma’s brand-new consultancy approach. Essential pillar of this evolution is Invents, the company’s innovation platform, positioning Bormioli Pharma as an innovation mobilizer, able to partner with the pharmaceutical industry to transform emerging healthcare needs into effective industrial solutions. The company’s experts will be available to visitors to explain the lean, open and scrum approach and to share new insights for possible co-developments, able to enhance the patient journey and experience, with better adaptation of different users and drug delivery routes. 

Through the consultancy approach presented at Pharmapack 2024, we want to reshape the traditional supplier-customer relationship in a more horizontal way, through co-development as a pivotal approach to accelerate pharma companies’ time-to-market” stated Andrea Lodetti, CEO of Bormioli Pharma. “We are ready to give our contribution to materialize the vision of the future of care as well as enabling the sustainable transition of our customers.”

Moreover, Bormioli Pharma will host a Learning Lab titled “How primary packaging can accelerate today’s drug development and approval process”. The Learning session will take place on January 25th from 10:50AM and will be focused on Bormioli Pharma’s well-grounded and extensive patient-centric innovation program intended to advise the pharma industry along the entire drug development process, from early-stage compatibility assessment up to the production of parts needed for drug filing, clinical trials and commercialization.

Bormioli Pharma

Bormioli Pharma works closely with the pharmaceutical industry and all companies that are working towards the future of healthcare globally. As a world-renowned player in the packaging industry, the company serves the pharmaceutical and biopharmaceutical markets with complete solutions, including glass and plastic bottles, plastic and aluminum closures and accessories. Bormioli Pharma’s wide product ranges are designed and manufactured looking forward innovation and addressing ever-growing sustainability issues. Moreover, each product is specifically conceived for the destination market thanks to an accurate portfolio segmentation. Bormioli Pharma has a global presence in over 100 countries, with more than 1,400 employees and 9 plants across Europe specialized in the production of glass and plastic packaging. Each year, the company produces more than 7 billion pieces and in 2022 reported annual sales of approximately 315 million euros. As a partner to the pharmaceutical industry, Bormioli Pharma invests and innovates with one goal in mind: making health a positive practice, available to everyone, and kind to the planet.

For further information:

Hill & Knowlton for Bormioli Pharma:

Daniele Rurale 

+39 346 5011546

Ilaria Carfì

+39 324 0114825

Share the Post:

Related Posts

Medicinal Plant Chicory

Chicory (Cichorium intybus L), a perennial herbaceous plant, is widespread throughout Europe. It is rich in inulin, which acts as a prebiotic and stimulates the growth of beneficial bacteria in the intestinal microflora.

Read More